Scynexis Company Profile (NASDAQ:SCYX)

About Scynexis

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Industry, Sector and Symbol:

Sector: Medical
Industry: Drugs - Generic
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: SCYX
CUSIP:

Key Metrics:

Previous Close: $4.03
50 Day Moving Average: $2.99
200 Day Moving Average: $3.18
52-Week Range: $1.74 - $7.69
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -2.06
P/E Growth: 0.00
Market Cap: $90.18M
Outstanding Shares: 23,424,000
Beta: 0.13

Profitability:

Net Margins: -12,239.31%
Return on Equity: -73.13%
Return on Assets: -62.60%

Debt:

Current Ratio: 11.67%
Quick Ratio: 11.67%

Additional Links:

Companies Related to Scynexis:

Consensus Ratings for Scynexis (NASDAQ:SCYX) (?)

Ratings Breakdown:	6 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$13.67 (239.12% upside)

Analysts' Ratings History for Scynexis (NASDAQ:SCYX)

Show:

Date	Firm	Action	Rating	Price Target
8/17/2016	Guggenheim	Initiated Coverage	Buy	$15.00
8/9/2016	WBB Securities	Upgrade	Speculative Buy -> Buy	$8.00
8/9/2016	Needham & Company LLC	Lower Price Target	Buy	$16.00 -> $10.00
8/8/2016	Brean Capital	Reiterated Rating	Buy
6/9/2016	Canaccord Genuity	Reiterated Rating	Buy
11/16/2015	Royal Bank Of Canada	Lower Price Target	Outperform	$18.00 -> $17.00

(Data available from 9/29/2014 forward)

Earnings History for Scynexis (NASDAQ:SCYX)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/11/2016
8/8/2016	Q216	($0.52)	($0.56)			View	N/A
5/9/2016	Q116	($0.63)	($0.52)			View	N/A
11/13/2015	Q315	($0.62)	($0.60)			View	N/A
5/15/2015	Q115	($0.43)	($0.75)	$4.20 million	$2.31 million	View	N/A
3/30/2015		($0.71)	($0.45)			View	N/A
11/13/2014		($0.53)	($0.45)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Scynexis (NASDAQ:SCYX)

Current Year EPS Consensus Estimate: $-1.89 EPS
Next Year EPS Consensus Estimate: $-1.96 EPS

Dividend History for Scynexis (NASDAQ:SCYX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Scynexis (NASDAQ:SCYX)

Insider Ownership Percentage: 3.91%
Institutional Ownership Percentage: 60.30%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/15/2016	Patrick Machado	Director	Buy	40,000	$2.94	$117,600.00
6/30/2016	Gonzalez David Angulo	Insider	Buy	36,950	$2.22	$82,029.00
6/24/2016	Eric Francois	CFO	Buy	15,000	$2.39	$35,850.00
6/24/2016	Guy Macdonald	Director	Buy	40,000	$2.39	$95,600.00
6/24/2016	Marco Taglietti	CEO	Buy	100,000	$2.39	$239,000.00
5/25/2016	Ann Hanham	Director	Buy	4,225	$3.64	$15,379.00
5/25/2016	Marco Taglietti	CEO	Buy	5,754	$3.26	$18,758.04
5/24/2016	Marco Taglietti	CEO	Buy	5,500	$3.37	$18,535.00
5/23/2016	Marco Taglietti	CEO	Buy	7,500	$3.14	$23,550.00
5/19/2016	Marco Taglietti	CEO	Buy	6,000	$3.07	$18,420.00
11/24/2015	Marco Taglietti	CEO	Buy	22,733	$6.79	$154,357.07
8/31/2015	Marco Taglietti	CEO	Buy	25,000	$7.82	$195,500.00
8/28/2015	Marco Taglietti	CEO	Buy	2,267	$7.08	$16,050.36
8/26/2015	Marco Taglietti	CEO	Buy	50,000	$7.07	$353,500.00
5/7/2014	Jean-Yves Nothias	Director	Buy	50,000	$10.00	$500,000.00
5/7/2014	Ventech Capital Ii	Major Shareholder	Buy	28,000	$10.00	$280,000.00

(Data available from 1/1/2013 forward)

Latest Headlines for Scynexis (NASDAQ:SCYX)

Date	Headline
	Stock Perspective: SCYNEXIS, Inc. (NASDAQ:SCYX) Company ... - Frisco Fastball (NASDAQ:SCYX) friscofastball.com - September 26 at 5:16 AM
	Pay Close Attention To These Analyst Ratings J M Smucker Co (NYSE:SJM), SCYNEXIS Inc (NASDAQ:SCYX) - The Voice Registrar (NASDAQ:SCYX) voiceregistrar.com - September 25 at 2:01 PM
	Could SCYNEXIS Inc See a Reversal After This Very Strong Session? - Post News (NASDAQ:SCYX) www.kentuckypostnews.com - September 25 at 2:01 PM
	Consensus Take: SCYNEXIS, Inc. (NASDAQ:SCYX) Earnings & Ratings Watch - Frisco Fastball (NASDAQ:SCYX) friscofastball.com - September 22 at 6:53 PM
	Analysts Set $16.00 Target Price for SCYNEXIS Inc (NASDAQ:SCYX) - DailyQuint (NASDAQ:SCYX) dailyquint.com - September 21 at 11:17 AM
	SCYNEXIS, Inc. to Present at the Ladenburg Thalmann Healthcare Conference - GlobeNewswire (press release) (NASDAQ:SCYX) globenewswire.com - September 21 at 11:17 AM
	SCYNEXIS, Inc. to Present at the Ladenburg Thalmann Healthcare Conference (NASDAQ:SCYX) finance.yahoo.com - September 20 at 12:33 PM
	ETF’s with exposure to SCYNEXIS, Inc. : September 19, 2016 (NASDAQ:SCYX) www.capitalcube.com - September 19 at 11:48 AM
	Stock Update, a Closer Look at SCYNEXIS, Inc. (NASDAQ:SCYX) - Duncan Research (NASDAQ:SCYX) www.duncanindependent.com - September 15 at 7:20 PM
	What is the Sell-side Saying About SCYNEXIS, Inc. (NASDAQ:SCYX)? - Frisco Fastball (NASDAQ:SCYX) friscofastball.com - September 15 at 7:20 PM
	Stock Perspective: SCYNEXIS, Inc. (NASDAQ:SCYX) Earnings in View - Frisco Fastball (NASDAQ:SCYX) friscofastball.com - September 15 at 10:52 AM
	Keen Investors Narrowing Their Focus on SCYNEXIS, Inc. (NASDAQ:SCYX) - Duncan Research (NASDAQ:SCYX) www.duncanindependent.com - September 15 at 10:52 AM
	Earnings Analysis & Update for SCYNEXIS, Inc. (NASDAQ:SCYX)? - Frisco Fastball (NASDAQ:SCYX) friscofastball.com - September 13 at 12:05 PM
	Will SCYNEXIS (SCYX) Continue to Surge Higher? (NASDAQ:SCYX) finance.yahoo.com - September 9 at 11:59 AM
	SCYNEXIS, Inc. to Present at Upcoming Investor Conferences - GlobeNewswire (press release) (NASDAQ:SCYX) globenewswire.com - September 1 at 7:11 PM
	ETF’s with exposure to SCYNEXIS, Inc. : September 1, 2016 (NASDAQ:SCYX) www.capitalcube.com - September 1 at 10:24 AM
	SCYNEXIS, Inc. to Present at Upcoming Investor Conferences (NASDAQ:SCYX) www.publicnow.com - August 31 at 12:37 PM
	New Market Research Report: Scynexis, Inc. (SCYX) - Financial and Strategic SWOT Analysis Review (NASDAQ:SCYX) www.live-pr.com - August 26 at 6:59 PM
	SCYNEXIS stock gets bump from orphan drug designation (NASDAQ:SCYX) wraltechwire.com - August 25 at 12:26 PM
	Scynexis (SCYX) Announces Receipt of FDA Orphan Drug Designation for SCY-078 as Aspergillus Infections Treatment (NASDAQ:SCYX) www.streetinsider.com - August 24 at 7:02 PM
	Scynexis (SCYX) Announces Receipt of FDA Orphan Drug Designation for SCY-078 as Aspergillus Infections Treatment - StreetInsider.com (NASDAQ:SCYX) www.streetinsider.com - August 24 at 10:25 AM
	SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections (NASDAQ:SCYX) www.publicnow.com - August 24 at 10:25 AM
	SCYNEXIS, Inc.'s (SCYX): Stock in Focus - Hot Stocks Point (NASDAQ:SCYX) www.hotstockspoint.com - August 22 at 7:14 PM
	ETF’s with exposure to SCYNEXIS, Inc. : August 18, 2016 (NASDAQ:SCYX) www.capitalcube.com - August 18 at 7:35 PM
	Analyst Upgrades: Valeant Pharmaceuticals Intl Inc, SCYNEXIS Inc, and Urban Outfitters, Inc. (NASDAQ:SCYX) www.schaeffersresearch.com - August 17 at 10:18 AM
	SCYNEXIS INC Financials (NASDAQ:SCYX) finance.yahoo.com - August 13 at 6:54 PM
	SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:SCYX) www.capitalcube.com - August 11 at 7:50 PM
	Scynexis upgraded by WBB Securities (NASDAQ:SCYX) finance.yahoo.com - August 9 at 10:34 AM
	Scynexis reports 2Q loss (NASDAQ:SCYX) www.cnbc.com - August 8 at 12:07 PM
	SCYNEXIS, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Update (NASDAQ:SCYX) www.publicnow.com - August 8 at 12:07 PM
	SCYNEXIS, Inc. to Present at the Canaccord Genuity Growth Conference - GlobeNewswire (press release) (NASDAQ:SCYX) globenewswire.com - August 5 at 7:33 PM
	SCYNEXIS, Inc. to Present at the Canaccord Genuity Growth Conference (NASDAQ:SCYX) finance.yahoo.com - August 4 at 10:33 AM
	SCYNEXIS Oral SCY-078 Achieves Target Exposure With Favorable Safety And Tolerability in Patients with Invasive Candidiasis (NASDAQ:SCYX) finance.yahoo.com - August 1 at 9:37 AM
	SCYNEXIS Announces Interim Results from Phase 2 Study of Oral SCY-078 in Patients with Invasive Candidiasis (NASDAQ:SCYX) www.publicnow.com - August 1 at 8:21 AM
	8:04 am Scynexis announces its Phase 2 study evaluating SCY-078 as a treatment in patients initially treated with IV echinocandin therapy for invasive Candida infections met all primary objectives (NASDAQ:SCYX) finance.yahoo.com - August 1 at 8:04 AM
	Insiders Increasing Positions in: SCYNEXIS, Inc. (NASDAQ:SCYX) - Press Telegraph (NASDAQ:SCYX) presstelegraph.com - July 21 at 7:38 PM
	Scynexis Incorporated (NASDAQ:SCYX) Shorted Shares Increased By 87.29% - Press Telegraph (NASDAQ:SCYX) presstelegraph.com - July 19 at 8:26 AM
	Investor Watch: Volatility Recap on Shares of: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily (NASDAQ:SCYX) www.engelwooddaily.com - July 19 at 8:26 AM
	New Broker Ratings For SCYNEXIS, Inc. (SCYX) - FTSE News (NASDAQ:SCYX) www.ftsenews.co.uk - July 19 at 8:26 AM
	Shares Moving Down on the Week: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily (NASDAQ:SCYX) www.engelwooddaily.com - July 17 at 11:23 AM
	SCYNEXIS, Inc. (SCYX) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:SCYX) www.fiscalstandard.com - July 17 at 11:23 AM
	Eye on Stock Volatility for: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily (NASDAQ:SCYX) www.engelwooddaily.com - July 15 at 12:34 PM
	Increased Volatility Noted on Shares of: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily (NASDAQ:SCYX) www.engelwooddaily.com - July 15 at 12:34 PM
	Broker Outlook For SCYNEXIS, Inc. (SCYX) - Fiscal Standard (NASDAQ:SCYX) www.fiscalstandard.com - July 15 at 12:34 PM
	Scynexis (SCYX) Sells Cyclophilin Inhibitor Assets to Cypralis - StreetInsider.com (NASDAQ:SCYX) www.streetinsider.com - July 13 at 7:42 PM
	Share Volatility Watch for: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily (NASDAQ:SCYX) www.engelwooddaily.com - July 13 at 7:42 PM
	SCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited (NASDAQ:SCYX) www.publicnow.com - July 13 at 8:48 AM
	Scynexis Incorporated (NASDAQ:SCYX) Short Interest Increased By 87.29% - Engelwood Daily (NASDAQ:SCYX) www.engelwooddaily.com - July 8 at 10:12 AM
	Following Unusual Volume for: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily (NASDAQ:SCYX) www.engelwooddaily.com - July 8 at 10:12 AM
	SCYNEXIS, Inc. to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference (NASDAQ:SCYX) www.publicnow.com - July 6 at 9:21 AM